Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Association of vitamin D receptor TaqI and ApaI genetic polymorphisms with nephrolithiasis and end stage renal disease: a meta-analysis

Source: Article title. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Review / evidence synthesis.

Review / evidence synthesis

Reviews existing research; the exact review methods need further assessment.

Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Association of vitamin D receptor TaqI and ApaI genetic polymorphisms with nephrolithiasis and end stage renal disease: a meta-analysis

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

Association of vitamin D receptor TaqI and ApaI genetic polymorphisms with nephrolithiasis and end stage renal disease: a meta-analysis

Review / evidence synthesis · BMC Medical Genetics · 2019

Original publication title

Association of vitamin D receptor TaqI and ApaI genetic polymorphisms with nephrolithiasis and end stage renal disease: a meta-analysis

Tajamul Hussain; Shaik M. Naushad; Anwar Ahmed; Salman Alamery; Arif A. Mohammed; Mohamed O. Abdelkader; Nasser Abobakr Nasser Alkhrm

© The Author(s). 2019

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

This meta-analysis revealed the association of VDR TaqI and ApaI polymorphisms with ESRD risk. This is the first meta-analysis study to simultaneously evaluate the association of DN, NL and ESRD with renal disease risk. Ethnicity, sample size, gene-environmental interactions appear to be responsible for inconsistencies observed in the association studies examining VDR polymorphisms and renal diseases. The limitations of this meta-analysis include; exclusion of studies where raw data or full text were not accessible and one-to-one correlation between vitamin D3 profile and risk could not be established as no parallel studies were conducted.

An extract from the source publication. Read it in context.

At a glance

Study background

What background does the paper provide?

In human skin, solar rays facilitate the formation of vitamin D3 from 7-dehydrocholesterol. The vitamin D3 undergoes two-step hydroxylation to form 25-hydroxy vitamin D3 (25-OHD3) and biologically active 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) [1]. Vitamin D receptor (VDR) is a ligand-activated transcriptional factor requiring 1,25(OH)2D for its activation [2]. The deficiency of 25OHD or VDR is reported to activate renin-angiotensin system resulting in high angiotensin II levels, which damage renal parenchyma leading to increased risk for renal disease [3].

Considering the pivotal role of VDR in maintaining normal renal function, a number of studies have explored the possibility of association of VDR gene polymorphisms with renal disease risk. Among VDR polymorphisms reported to date, ApaI, and TaqI are widely studied for their association with ESRD, NL and DN [4Not reported6]. The ApaI variant (rs7975232), which results in A to C transition, is located in the intron 8 of VDR gene, while TaqI variant (rs731236), which results in T to C transition is located in exon 9 [7].

The rs7975232 (NG_008731.1:g.64978G > T) is an intronic variant predicted to influence splice site changes that might affect the translation of VDR. The frequency of this variant is high as evidenced by 734 and 16,751 homozygous mutants in 1000G and ExAC databases. The rs731236 (NG_008731.1:g.65058 T > C) variant is near the exon-intron boundary (GCTG/attg) and hence likely to influence splicing and thus might affect the translation of VDR. The frequency of this variant is lower than that of rs7975232 with 242 and 7505 homozygous mutants identified in 1000G and ExAC databases.

Importantly, genetic studies examining the role of TakI and ApaI polymorphisms in the pathogeneses of NL, DN and ESRD remained ambiguous [4Not reported6, 8Not reported12]. Considering the significance of VDR signaling in the protection against renal diseases and the ambiguity in the studies relating VDR gene polymorphism with the disease etiology, present meta-analysis comprising 2669 renal disease cases and 3342 controls was carried out to clarify the association of VDR gene TaqI and ApaI polymorphisms with nephrolithiasis, ESRD and diabetic nephropathy.

Upon reviewer's suggestion the data related this sentence has been removed from the manuscript, regrettably we failed to delete this sentence in our revised submission.

Source: Introduction Source: Introduction Source: Introduction

Study methods

What methods does the paper describe?

Data extraction

The literature retrieval was carried out using keywords: vitamin D receptor or VDR, renal disease, nephrolithiasis or urolithiasis, diabetic nephropathy, TaqI (rs731236) and ApaI (rs7975232) in PubMed, Medline and google scholar databases. All the free full texts were retrieved and wherever full text was not available, reprint request was sent to the corresponding author of the respective article. The criteria to include in the meta-analysis were: 1) availability of full text of the article, 2) inclusion of studies involving both cases and controls (either online or through reprint from the corresponding author), 3) availability of raw data on genotypes, and 4) restricting to studies published in only English language.

The information related to each study such as first author, year of study, ethnic group or population studied, distribution of genotypes in cases and controls etc. was computed. The decision on the studies to be included in meta-analysis was taken by all the authors of this study.

Meta-analysis

The data computed in four columns wherein first two columns represent the number of variant alleles in cases and controls and last two columns represent the number of ancestral alleles in cases and controls. Log (odds ratio) or effect size and standard error (SE) are calculated based on these four column data. Based on these two parameters, variance (SE2), weight and 95% confidence interval of effect size were calculated. Cochrane Q test and I2 statistics were performed to test the heterogeneity in the association.

The plot of 1/SE and Z-statistics was also used as an index to test heterogeneity. The publication bias was based on the rank correlation of SE and v. The fixed effect and random effect models were generated based on Mantel Haenszel and DerSimonian Lair’s methods, respectively. If no evidence of heterogeneity was found, fixed effect model was considered. If test heterogeneity was significant, random effect model was considered.

Source: Methods Source: Methods

Discussion

Deficiency of vitamin D or defective activation of VDR by its ligand, 1,25-dihydroxy vitamin D results in secondary hyperparathyroidism, angiotensin II-mediated renal damage and renal disease pathogenesis [3]. On the other hand, VDR activation suppressed inflammatory cell infiltration and inhibited nuclear factor-κB activation [30]. Likewise, active vitamin D3 and lentivirus-mediated transforming growth factor-β (TGF-β) interference effectively reduced renal fibrosis in rat models [31]. These observations highlight the importance of VDR signaling in maintaining normal renal function.

Accordingly, a number of studies have investigated the effects of polymorphisms in VDR gene on renal disease etiology. Among these, TaqI, and ApaI polymorphisms are widely studied [4Not reported6]. However, there is a considerable ambiguity among these genetic studies, possibly stemming from sample size, ethnicity or gene-environmental interactions [4Not reported6, 8Not reported12]. To clarify whether TaqI and apaI polymorphisms have a role in renal disease pathogenesis, this meta-analysis comprising 2777 renal disease cases including DN, NL and ESRD and 3522 healthy controls was carried out.

The present meta-analysis revealed an increased disease risk for subjects harboring TaqI C-allele under fixed and random effect models. Subgroup analysis based on type of renal disease showed that VDR TaqI polymorphism is associated with ESRD in allele contrast model, whereas no significant association was found between TaqI polymorphism and DN and NL. In the case of ApaI polymorphism, Apal C-allele was found to be linked to ESRD, but not with DM or NL under fixed effect model. Earlier, Yang et al. performed a meta-analysis on 1510 cases and 1812 controls and found no association of BsmI, FokI, TaqI, and ApaI polymorphisms of VDR with end-stage renal disease.

Inclusion of more studies benefited the current meta-analysis.

The direct role of solar rays in the synthesis of vitamin D is well known. In human skin, solar rays facilitate the formation of vitamin D3 from 7-dehydrocholesterol, which is evident from the presence of higher mean serum vitamin D levels in summer than in winter [32]. Likewise, higher vitamin D levels were found in populations living in regions known to have longer durations of sun exposure [33].

Source: Discussion Source: Discussion

Results

Figure 1 depicts the data extraction process for the meta-analysis. Of the 16 case-control studies retrieved on the association of TaqI polymorphism with renal disease (Table 1), four studies showed deviation from Hardy-Weinberg equilibrium [7, 13Not reported15]. Among the different population groups included in this meta-analysis, the largest being that of Turkish representing five case-control studies [16Not reported20], two studies from India [21, 22] and one each from China [23], Ireland [24], Italy [25], Spain [26] and Croatia [27].

In total, the final meta-analysis was based on the data of 2777 cases and 3522 controls representing 16 case-control studies.

Fig. 1

PRISMA flowchart showing the steps in meta-analysis data extraction

Figure image at the original source: open the original paper. This file is not included in this text import.

Table 1

Distribution of VDR1 TaqI polymorphism in different case-control studies

AuthorYearCountryRenal disease typeGenotypesC-allele frequency
CasesControl
TTTCCCTTTCCCCasesControl
Wang [23]2016ChinaESRD21519740474358720.310.28
Cakir [20]2016TurkeyNL3544193129100.420.35
Guha [13]2015IndiaNL5882606558770.510.53
Martin [24]2010IrelandDN225327103249327980.410.39
Ozkaya [16]2003TurkeyNL332745030100.270.28
Mossetti [25]2003ItalyNL80104363566130.400.40
Bucan [27]2009CroatiaDN563131460.430.39
Nosratabadi [7]2010IranDN95536463330.640.65
Goknar [15]2016TurkeyNL254112144330.420.41
Tripathi [21]2010IndiaESRD10511538267228740.370.33
Mittal [22]2010IndiaNL566188450160.310.27
Moyano [26]2007SpainNL15231391110.480.31
Gunes [17]2006TurkeyNL3763106173160.380.35
Seyhan [18]2007TurkeyNL273518132520.440.36
Aykan [19]2015TurkeyNL6761366686150.410.35
Han [14]2015ChinaNL102601601640.030.07

The following studies were shown to have deviation from HWE: Guha et al. (p < 0.0001), Nosratabadi et al. (p = 0.0008), Goknar et al. (p = 0.0008) and Han et al. (p = 0.0008)

ESRD end stage renal disease, NL nephrolithiasis, DN diabetic nephropathy

Cochrane Q-test (Q: 13.72, p = 0.54) and I2 (0.00) statistics showed no evidence of heterogeneity in association. Egger’s test revealed no evidence of publication bias (p = 0.14). The VDR TaqI C-allele, under allele contrast fixed effect model, was associated with renal diseases calculated collectively for DN, ESRD and NL (OR: 1.11, 95% CI: 1.03 to 1.20, p = 0.008). (Figure 2) As shown Table 2, subtype analysis revealed Taql C: allele to be associated with ESRD (OR: 1.17, 95% CI: 1.02 to 1.34, p = 0.03) (Fig. 2).

Among the different ethnic groups, Turkish population showed strong association between VDR TaqI polymorphism and renal disease in allele contrast model (C vs. T, OR: 1.19, 95% CI: 1.01 to 1.42, p = 0.04). Sensitivity analysis revealed that omitting either of the studies had no effect on overall outcome of disease risk.

Fig. 2

Meta-analysis of association studies on VDR TaqI polymorphism vs. risk for renal disease. Forest plot: The terms experimental and control groups corresponds to cases and controls. Number of variant alleles was considered as events with respect to total number of alleles tested. This meta-analysis was based on 16 case-control studies representing seven population groups. VDR TaqI polymorphism was shown to exert risk for renal disease both in fixed effect and random effect models. Funnel Diagram: It is depicting that no heterogeneity in association.

Sensitivity analysis: Exclusion of any of the study is not influencing the result

Figure image at the original source: open the original paper. This file is not included in this text import.

Table 2

Subgroup analysis showing disease-specific risk with VDR TaqI polymorphism

ModelType of diseaseNOR95% CIP value
Allele contrast (A vs. a)Overall161.11[1.0262; 1.1967]0.009
ESRD21.17[1.0171; 1.3357]0.028
NL111.09[0.9673; 1.2356]0.153
DN31.07[0.9250; 1.2322]0.371
Recessive model (AA vs. Aa+aa)Overall161.19[0.9266; 1.5392]0.170
ESRD21.14[0.8497; 1.5235]0.386
NL111.32[0.8084; 2.1503]0.268
DN31.11[0.8527; 1.4432]0.439
Dominant model (AA+Aa vs. aa)Overall161.14[1.0234; 1.2709]0.017
ESRD21.24[1.0367; 1.4863]0.019
NL111.09[0.9148; 1.2930]0.342
DN31.09[0.8737; 1.3505]0.456
Overdominant (Aa vs. AA + aa)Overall160.99[0.8106; 1.2040]0.904
ESRD21.19[0.9904; 1.4233]0.063
NL110.92[0.6575; 1.2975]0.647
DN31.01[0.8261; 1.2289]0.940
pairw1 (AA vs. aa)Overall161.20[1.0117; 1.4232]0.036
ESRD21.26[0.9280; 1.7151]0.138
NL111.23[0.9346; 1.6077]0.141
DN31.11[0.8081; 1.5149]0.528
pairw2 (AA vs. Aa)Overall161.16[0.8525; 1.5857]0.341
ESRD21.01[0.7443; 1.3803]0.932
NL111.30[0.7200; 2.3483]0.384
DN31.09[0.8304; 1.4407]0.524
pairw3 (Aa vs. aa)Overall161.09[0.9167; 1.2888]0.337
ESRD21.24[1.0233; 1.4966]0.028
NL111.04[0.7873; 1.3666]0.795
DN31.07[0.8487; 1.3425]0.577

Of the 13 case-control studies (2440 cases and 3279 controls) retrieved on the association of ApaI polymorphism with renal disease (Table 3), five studies deviated from Hardy-Weinberg equilibrium [7, 15, 19, 21, 28]. Among the studies in accordance with HWE equilibrium, 3 studies were from Turkey [16, 17, 20], two from China [14, 23], and one each from Ireland [24] and Iran [29].

Cochrane Q-test (Q: 17.01, p = 0.03) and I2 (48.3) statistics showed high-degree of heterogeneity in association. Egger’s test revealed no evidence of publication bias (p = 0.54). The fixed effect model showed positive association of VDR ApaI polymorphism with all the renal disease cases (C vs. A, OR: 1.10, 95% CI: 1.01 to 1.19), whereas, random effect model showed null association (OR: 1.05, 95% CI: 0.93 to 1.19) (Fig. 3). Sensitivity analysis for ApaI polymorphism revealed that the sources of heterogeneity are two studies i.e. Wang et al. and Tripathi et al. However, overall trend suggests ApaI variant as a risk factor for renal disease.

As shown in Table 4, subgroup analysis revealed association of VDR ApaI polymorphism with ESRD (C vs. A, OR: 1.31, 95% CI: 1.15 to 1.50, p = 0.0001) and no association with NL and DN.

Table 3

Distribution of VDR1 ApaI polymorphism across different case-controls studies

AuthorYearCountryRenal disease typeGenotypesC-allele frequency
CasesControl
AAACCCAAACCCCasesControls
Wang [23]2016ChinaESRD20620739502350520.320.25
Cakir [20]2016TurkeyNL4340152634100.360.39
Ghorbanihaghjo [29]2014IranCH1023131616110.530.44
Martin [24]2010IrelandDN1853231472003221520.470.46
Ozkaya [16]2003TurkeyNL133021450360.560.68
Zhang [28]2012ChinaDN1989741165460.650.64
Han [14]2015ChinaDN250561880820.750.68
Nosratabadi [7]2010IranDN96427963280.590.60
Goknar [15]2016TurkeyNL244212114090.420.48
Tripathi [21]2010IndiaESRD8011662171324740.470.41
Mittal [22]2010IndiaNL4370125771220.380.38
Gunes [17]2006TurkeyNL4058125972190.370.37
Aykan [19]2015TurkeyNL1451451201550.900.93

The following studies were shown to have deviation from HWE: Ozkaya et al. (p = 0.03), Nosratabadi et al. (p = 0.009), Goknar et al. (p = 0.03), Tripathi et al. (p < 0.0001) and Aykan et al. (p < 0.0001)

ESRD end stage renal disease, NL nephrolithiasis, CH chronic hemodialysis, DN diabetic nephropathy

Fig. 3

Meta-analysis of association studies on VDR ApaI polymorphism vs. risk for renal disease. Forest plot: The terms experimental and control groups correspond to cases and controls. Number of variant alleles were considered as events with respect to total number of alleles tested. This meta-analysis was based on 13 case-control studies representing 5 population groups. VDR ApaI polymorphism was shown to exert risk for renal disease only in fixed effect model, but not in random effect model. Funnel Diagram: It is depicting that two studies are contributing to heterogeneity.

Sensitivity analysis: Excluding two studies is influencing the results

Figure image at the original source: open the original paper. This file is not included in this text import.

Table 4

Subgroup analysis showing disease-specific risk with VDR ApaI polymorphism

ModelType of diseaseNOR95% CIp-val
Allele contrast (A vs. a)Overall131.05[0.9282; 1.1931]0.4259
ESRD21.31[1.1454; 1.4996]0.0001
NL60.86[0.7193; 1.0175]0.0777
CH11.44[0.7974; 2.5983]0.2268
DN41.06[0.9361; 1.1997]0.3589
Recessive model (AA vs. Aa+aa)Overall131.10[0.8891; 1.3548]0.3865
ESRD21.85[1.3925; 2.4544]0.0000
NL60.77[0.5591; 1.0553]0.1035
CH11.15[0.4482; 2.9300]0.7760
DN41.06[0.8695; 1.2818]0.5840
Dominant model (AA+Aa vs. aa)Overall131.03[0.8131; 1.3008]0.8153
ESRD21.21[0.7844; 1.8716]0.3868
NL60.76[0.5034; 1.1586]0.2049
CH12.13[0.8380; 5.4311]0.1120
DN41.09[0.8749; 1.3545]0.4466
Overdominant (Aa vs. AA + aa)Overall130.99[0.8143; 1.2066]0.9300
ESRD20.91[0.4290; 1.9490]0.8167
NL60.96[0.6559; 1.3933]0.8147
CH11.69[0.7239; 3.9340]0.2256
DN41.03[0.8660; 1.2221]0.7472
pairw1 (AA vs. aa)Overall131.09[0.8006; 1.4779]0.5907
ESRD21.81[1.3275; 2.4638]0.0002
NL60.70[0.4803; 1.0158]0.0604
CH11.89[0.6130; 5.8330]0.2677
DN41.09[0.8307; 1.4252]0.5399
pairw2 (AA vs. Aa)Overall131.10[0.8709; 1.3854]0.4280
ESRD21.74[0.9540; 3.1683]0.0709
NL60.86[0.5968; 1.2327]0.4068
CH10.82[0.2948; 2.2927]0.7082
DN41.02[0.8306; 1.2477]0.8635
pairw3 (Aa vs. aa)Overall131.03[0.7832; 1.3445]0.8515
ESRD21.06[0.5720; 1.9761]0.8464
NL60.79[0.4507; 1.3857]0.4113
CH12.30[0.8331; 6.3500]0.1080
DN41.10[0.8688; 1.3802]0.4417
Source: Results Source: Results Source: Results

Conclusions

This meta-analysis revealed the association of VDR TaqI and ApaI polymorphisms with ESRD risk. This is the first meta-analysis study to simultaneously evaluate the association of DN, NL and ESRD with renal disease risk. Ethnicity, sample size, gene-environmental interactions appear to be responsible for inconsistencies observed in the association studies examining VDR polymorphisms and renal diseases. The limitations of this meta-analysis include; exclusion of studies where raw data or full text were not accessible and one-to-one correlation between vitamin D3 profile and risk could not be established as no parallel studies were conducted.

Source: Conclusions
Authors’ abstract

Background

The deficiency of vitamin D receptor (VDR) or its ligand, vitamin D3, is linked to the development of renal diseases. The TaqI (rs731236) and ApaI (rs7975232) polymorphisms of VDR gene are widely studied for their association with renal disease risk. However, studies have largely been ambiguous.

Methods

Meta-analysis was carried out to clarify the association of TaqI (2777 cases and 3522 controls) and ApaI (2440 cases and 3279 controls) polymorphisms with nephrolithiasis (NL), diabetic nephropathy (DN) and end stage renal disease (ESRD).

Results

The VDR TaqI C-allele under allele contrast was significantly associated with ESRD in both fixed effect and random effect models, and ApaI C-allele with ESRD only under fixed effect model. Cochrane Q-test showed no evidence of heterogeneity for TaqI polymorphism and a significant heterogeneity for Apa I polymorphism. No publication bias was observed for both the polymorphisms.

Conclusions

The present meta-analysis identifies TaqI and ApaI polymorphisms of VDR gene as risk factors for renal diseases.

Read the full paper

Introduction

In human skin, solar rays facilitate the formation of vitamin D3 from 7-dehydrocholesterol. The vitamin D3 undergoes two-step hydroxylation to form 25-hydroxy vitamin D3 (25-OHD3) and biologically active 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) [1]. Vitamin D receptor (VDR) is a ligand-activated transcriptional factor requiring 1,25(OH)2D for its activation [2]. The deficiency of 25OHD or VDR is reported to activate renin-angiotensin system resulting in high angiotensin II levels, which damage renal parenchyma leading to increased risk for renal disease [3].

Considering the pivotal role of VDR in maintaining normal renal function, a number of studies have explored the possibility of association of VDR gene polymorphisms with renal disease risk. Among VDR polymorphisms reported to date, ApaI, and TaqI are widely studied for their association with ESRD, NL and DN [4Not reported6]. The ApaI variant (rs7975232), which results in A to C transition, is located in the intron 8 of VDR gene, while TaqI variant (rs731236), which results in T to C transition is located in exon 9 [7].

The rs7975232 (NG_008731.1:g.64978G > T) is an intronic variant predicted to influence splice site changes that might affect the translation of VDR. The frequency of this variant is high as evidenced by 734 and 16,751 homozygous mutants in 1000G and ExAC databases. The rs731236 (NG_008731.1:g.65058 T > C) variant is near the exon-intron boundary (GCTG/attg) and hence likely to influence splicing and thus might affect the translation of VDR. The frequency of this variant is lower than that of rs7975232 with 242 and 7505 homozygous mutants identified in 1000G and ExAC databases.

Importantly, genetic studies examining the role of TakI and ApaI polymorphisms in the pathogeneses of NL, DN and ESRD remained ambiguous [4Not reported6, 8Not reported12]. Considering the significance of VDR signaling in the protection against renal diseases and the ambiguity in the studies relating VDR gene polymorphism with the disease etiology, present meta-analysis comprising 2669 renal disease cases and 3342 controls was carried out to clarify the association of VDR gene TaqI and ApaI polymorphisms with nephrolithiasis, ESRD and diabetic nephropathy.

Upon reviewer's suggestion the data related this sentence has been removed from the manuscript, regrettably we failed to delete this sentence in our revised submission.

Methods

Data extraction

The literature retrieval was carried out using keywords: vitamin D receptor or VDR, renal disease, nephrolithiasis or urolithiasis, diabetic nephropathy, TaqI (rs731236) and ApaI (rs7975232) in PubMed, Medline and google scholar databases. All the free full texts were retrieved and wherever full text was not available, reprint request was sent to the corresponding author of the respective article. The criteria to include in the meta-analysis were: 1) availability of full text of the article, 2) inclusion of studies involving both cases and controls (either online or through reprint from the corresponding author), 3) availability of raw data on genotypes, and 4) restricting to studies published in only English language.

The information related to each study such as first author, year of study, ethnic group or population studied, distribution of genotypes in cases and controls etc. was computed. The decision on the studies to be included in meta-analysis was taken by all the authors of this study.

Meta-analysis

The data computed in four columns wherein first two columns represent the number of variant alleles in cases and controls and last two columns represent the number of ancestral alleles in cases and controls. Log (odds ratio) or effect size and standard error (SE) are calculated based on these four column data. Based on these two parameters, variance (SE2), weight and 95% confidence interval of effect size were calculated. Cochrane Q test and I2 statistics were performed to test the heterogeneity in the association.

The plot of 1/SE and Z-statistics was also used as an index to test heterogeneity. The publication bias was based on the rank correlation of SE and v. The fixed effect and random effect models were generated based on Mantel Haenszel and DerSimonian Lair’s methods, respectively. If no evidence of heterogeneity was found, fixed effect model was considered. If test heterogeneity was significant, random effect model was considered.

Results

Figure 1 depicts the data extraction process for the meta-analysis. Of the 16 case-control studies retrieved on the association of TaqI polymorphism with renal disease (Table 1), four studies showed deviation from Hardy-Weinberg equilibrium [7, 13Not reported15]. Among the different population groups included in this meta-analysis, the largest being that of Turkish representing five case-control studies [16Not reported20], two studies from India [21, 22] and one each from China [23], Ireland [24], Italy [25], Spain [26] and Croatia [27].

In total, the final meta-analysis was based on the data of 2777 cases and 3522 controls representing 16 case-control studies.

Fig. 1

PRISMA flowchart showing the steps in meta-analysis data extraction

Figure image at the original source: open the original paper. This file is not included in this text import.

Table 1

Distribution of VDR1 TaqI polymorphism in different case-control studies

AuthorYearCountryRenal disease typeGenotypesC-allele frequency
CasesControl
TTTCCCTTTCCCCasesControl
Wang [23]2016ChinaESRD21519740474358720.310.28
Cakir [20]2016TurkeyNL3544193129100.420.35
Guha [13]2015IndiaNL5882606558770.510.53
Martin [24]2010IrelandDN225327103249327980.410.39
Ozkaya [16]2003TurkeyNL332745030100.270.28
Mossetti [25]2003ItalyNL80104363566130.400.40
Bucan [27]2009CroatiaDN563131460.430.39
Nosratabadi [7]2010IranDN95536463330.640.65
Goknar [15]2016TurkeyNL254112144330.420.41
Tripathi [21]2010IndiaESRD10511538267228740.370.33
Mittal [22]2010IndiaNL566188450160.310.27
Moyano [26]2007SpainNL15231391110.480.31
Gunes [17]2006TurkeyNL3763106173160.380.35
Seyhan [18]2007TurkeyNL273518132520.440.36
Aykan [19]2015TurkeyNL6761366686150.410.35
Han [14]2015ChinaNL102601601640.030.07

The following studies were shown to have deviation from HWE: Guha et al. (p < 0.0001), Nosratabadi et al. (p = 0.0008), Goknar et al. (p = 0.0008) and Han et al. (p = 0.0008)

ESRD end stage renal disease, NL nephrolithiasis, DN diabetic nephropathy

Cochrane Q-test (Q: 13.72, p = 0.54) and I2 (0.00) statistics showed no evidence of heterogeneity in association. Egger’s test revealed no evidence of publication bias (p = 0.14). The VDR TaqI C-allele, under allele contrast fixed effect model, was associated with renal diseases calculated collectively for DN, ESRD and NL (OR: 1.11, 95% CI: 1.03 to 1.20, p = 0.008). (Figure 2) As shown Table 2, subtype analysis revealed Taql C: allele to be associated with ESRD (OR: 1.17, 95% CI: 1.02 to 1.34, p = 0.03) (Fig. 2).

Among the different ethnic groups, Turkish population showed strong association between VDR TaqI polymorphism and renal disease in allele contrast model (C vs. T, OR: 1.19, 95% CI: 1.01 to 1.42, p = 0.04). Sensitivity analysis revealed that omitting either of the studies had no effect on overall outcome of disease risk.

Fig. 2

Meta-analysis of association studies on VDR TaqI polymorphism vs. risk for renal disease. Forest plot: The terms experimental and control groups corresponds to cases and controls. Number of variant alleles was considered as events with respect to total number of alleles tested. This meta-analysis was based on 16 case-control studies representing seven population groups. VDR TaqI polymorphism was shown to exert risk for renal disease both in fixed effect and random effect models. Funnel Diagram: It is depicting that no heterogeneity in association.

Sensitivity analysis: Exclusion of any of the study is not influencing the result

Figure image at the original source: open the original paper. This file is not included in this text import.

Table 2

Subgroup analysis showing disease-specific risk with VDR TaqI polymorphism

ModelType of diseaseNOR95% CIP value
Allele contrast (A vs. a)Overall161.11[1.0262; 1.1967]0.009
ESRD21.17[1.0171; 1.3357]0.028
NL111.09[0.9673; 1.2356]0.153
DN31.07[0.9250; 1.2322]0.371
Recessive model (AA vs. Aa+aa)Overall161.19[0.9266; 1.5392]0.170
ESRD21.14[0.8497; 1.5235]0.386
NL111.32[0.8084; 2.1503]0.268
DN31.11[0.8527; 1.4432]0.439
Dominant model (AA+Aa vs. aa)Overall161.14[1.0234; 1.2709]0.017
ESRD21.24[1.0367; 1.4863]0.019
NL111.09[0.9148; 1.2930]0.342
DN31.09[0.8737; 1.3505]0.456
Overdominant (Aa vs. AA + aa)Overall160.99[0.8106; 1.2040]0.904
ESRD21.19[0.9904; 1.4233]0.063
NL110.92[0.6575; 1.2975]0.647
DN31.01[0.8261; 1.2289]0.940
pairw1 (AA vs. aa)Overall161.20[1.0117; 1.4232]0.036
ESRD21.26[0.9280; 1.7151]0.138
NL111.23[0.9346; 1.6077]0.141
DN31.11[0.8081; 1.5149]0.528
pairw2 (AA vs. Aa)Overall161.16[0.8525; 1.5857]0.341
ESRD21.01[0.7443; 1.3803]0.932
NL111.30[0.7200; 2.3483]0.384
DN31.09[0.8304; 1.4407]0.524
pairw3 (Aa vs. aa)Overall161.09[0.9167; 1.2888]0.337
ESRD21.24[1.0233; 1.4966]0.028
NL111.04[0.7873; 1.3666]0.795
DN31.07[0.8487; 1.3425]0.577

Of the 13 case-control studies (2440 cases and 3279 controls) retrieved on the association of ApaI polymorphism with renal disease (Table 3), five studies deviated from Hardy-Weinberg equilibrium [7, 15, 19, 21, 28]. Among the studies in accordance with HWE equilibrium, 3 studies were from Turkey [16, 17, 20], two from China [14, 23], and one each from Ireland [24] and Iran [29].

Cochrane Q-test (Q: 17.01, p = 0.03) and I2 (48.3) statistics showed high-degree of heterogeneity in association. Egger’s test revealed no evidence of publication bias (p = 0.54). The fixed effect model showed positive association of VDR ApaI polymorphism with all the renal disease cases (C vs. A, OR: 1.10, 95% CI: 1.01 to 1.19), whereas, random effect model showed null association (OR: 1.05, 95% CI: 0.93 to 1.19) (Fig. 3). Sensitivity analysis for ApaI polymorphism revealed that the sources of heterogeneity are two studies i.e. Wang et al. and Tripathi et al. However, overall trend suggests ApaI variant as a risk factor for renal disease.

As shown in Table 4, subgroup analysis revealed association of VDR ApaI polymorphism with ESRD (C vs. A, OR: 1.31, 95% CI: 1.15 to 1.50, p = 0.0001) and no association with NL and DN.

Table 3

Distribution of VDR1 ApaI polymorphism across different case-controls studies

AuthorYearCountryRenal disease typeGenotypesC-allele frequency
CasesControl
AAACCCAAACCCCasesControls
Wang [23]2016ChinaESRD20620739502350520.320.25
Cakir [20]2016TurkeyNL4340152634100.360.39
Ghorbanihaghjo [29]2014IranCH1023131616110.530.44
Martin [24]2010IrelandDN1853231472003221520.470.46
Ozkaya [16]2003TurkeyNL133021450360.560.68
Zhang [28]2012ChinaDN1989741165460.650.64
Han [14]2015ChinaDN250561880820.750.68
Nosratabadi [7]2010IranDN96427963280.590.60
Goknar [15]2016TurkeyNL244212114090.420.48
Tripathi [21]2010IndiaESRD8011662171324740.470.41
Mittal [22]2010IndiaNL4370125771220.380.38
Gunes [17]2006TurkeyNL4058125972190.370.37
Aykan [19]2015TurkeyNL1451451201550.900.93

The following studies were shown to have deviation from HWE: Ozkaya et al. (p = 0.03), Nosratabadi et al. (p = 0.009), Goknar et al. (p = 0.03), Tripathi et al. (p < 0.0001) and Aykan et al. (p < 0.0001)

ESRD end stage renal disease, NL nephrolithiasis, CH chronic hemodialysis, DN diabetic nephropathy

Fig. 3

Meta-analysis of association studies on VDR ApaI polymorphism vs. risk for renal disease. Forest plot: The terms experimental and control groups correspond to cases and controls. Number of variant alleles were considered as events with respect to total number of alleles tested. This meta-analysis was based on 13 case-control studies representing 5 population groups. VDR ApaI polymorphism was shown to exert risk for renal disease only in fixed effect model, but not in random effect model. Funnel Diagram: It is depicting that two studies are contributing to heterogeneity.

Sensitivity analysis: Excluding two studies is influencing the results

Figure image at the original source: open the original paper. This file is not included in this text import.

Table 4

Subgroup analysis showing disease-specific risk with VDR ApaI polymorphism

ModelType of diseaseNOR95% CIp-val
Allele contrast (A vs. a)Overall131.05[0.9282; 1.1931]0.4259
ESRD21.31[1.1454; 1.4996]0.0001
NL60.86[0.7193; 1.0175]0.0777
CH11.44[0.7974; 2.5983]0.2268
DN41.06[0.9361; 1.1997]0.3589
Recessive model (AA vs. Aa+aa)Overall131.10[0.8891; 1.3548]0.3865
ESRD21.85[1.3925; 2.4544]0.0000
NL60.77[0.5591; 1.0553]0.1035
CH11.15[0.4482; 2.9300]0.7760
DN41.06[0.8695; 1.2818]0.5840
Dominant model (AA+Aa vs. aa)Overall131.03[0.8131; 1.3008]0.8153
ESRD21.21[0.7844; 1.8716]0.3868
NL60.76[0.5034; 1.1586]0.2049
CH12.13[0.8380; 5.4311]0.1120
DN41.09[0.8749; 1.3545]0.4466
Overdominant (Aa vs. AA + aa)Overall130.99[0.8143; 1.2066]0.9300
ESRD20.91[0.4290; 1.9490]0.8167
NL60.96[0.6559; 1.3933]0.8147
CH11.69[0.7239; 3.9340]0.2256
DN41.03[0.8660; 1.2221]0.7472
pairw1 (AA vs. aa)Overall131.09[0.8006; 1.4779]0.5907
ESRD21.81[1.3275; 2.4638]0.0002
NL60.70[0.4803; 1.0158]0.0604
CH11.89[0.6130; 5.8330]0.2677
DN41.09[0.8307; 1.4252]0.5399
pairw2 (AA vs. Aa)Overall131.10[0.8709; 1.3854]0.4280
ESRD21.74[0.9540; 3.1683]0.0709
NL60.86[0.5968; 1.2327]0.4068
CH10.82[0.2948; 2.2927]0.7082
DN41.02[0.8306; 1.2477]0.8635
pairw3 (Aa vs. aa)Overall131.03[0.7832; 1.3445]0.8515
ESRD21.06[0.5720; 1.9761]0.8464
NL60.79[0.4507; 1.3857]0.4113
CH12.30[0.8331; 6.3500]0.1080
DN41.10[0.8688; 1.3802]0.4417

Discussion

Deficiency of vitamin D or defective activation of VDR by its ligand, 1,25-dihydroxy vitamin D results in secondary hyperparathyroidism, angiotensin II-mediated renal damage and renal disease pathogenesis [3]. On the other hand, VDR activation suppressed inflammatory cell infiltration and inhibited nuclear factor-κB activation [30]. Likewise, active vitamin D3 and lentivirus-mediated transforming growth factor-β (TGF-β) interference effectively reduced renal fibrosis in rat models [31]. These observations highlight the importance of VDR signaling in maintaining normal renal function.

Accordingly, a number of studies have investigated the effects of polymorphisms in VDR gene on renal disease etiology. Among these, TaqI, and ApaI polymorphisms are widely studied [4Not reported6]. However, there is a considerable ambiguity among these genetic studies, possibly stemming from sample size, ethnicity or gene-environmental interactions [4Not reported6, 8Not reported12]. To clarify whether TaqI and apaI polymorphisms have a role in renal disease pathogenesis, this meta-analysis comprising 2777 renal disease cases including DN, NL and ESRD and 3522 healthy controls was carried out.

The present meta-analysis revealed an increased disease risk for subjects harboring TaqI C-allele under fixed and random effect models. Subgroup analysis based on type of renal disease showed that VDR TaqI polymorphism is associated with ESRD in allele contrast model, whereas no significant association was found between TaqI polymorphism and DN and NL. In the case of ApaI polymorphism, Apal C-allele was found to be linked to ESRD, but not with DM or NL under fixed effect model. Earlier, Yang et al. performed a meta-analysis on 1510 cases and 1812 controls and found no association of BsmI, FokI, TaqI, and ApaI polymorphisms of VDR with end-stage renal disease.

Inclusion of more studies benefited the current meta-analysis.

The direct role of solar rays in the synthesis of vitamin D is well known. In human skin, solar rays facilitate the formation of vitamin D3 from 7-dehydrocholesterol, which is evident from the presence of higher mean serum vitamin D levels in summer than in winter [32]. Likewise, higher vitamin D levels were found in populations living in regions known to have longer durations of sun exposure [33].

Conclusions

This meta-analysis revealed the association of VDR TaqI and ApaI polymorphisms with ESRD risk. This is the first meta-analysis study to simultaneously evaluate the association of DN, NL and ESRD with renal disease risk. Ethnicity, sample size, gene-environmental interactions appear to be responsible for inconsistencies observed in the association studies examining VDR polymorphisms and renal diseases. The limitations of this meta-analysis include; exclusion of studies where raw data or full text were not accessible and one-to-one correlation between vitamin D3 profile and risk could not be established as no parallel studies were conducted.

Abbreviations

1,25 (OH)2D3

1,25-dihydroxyvitamin D3

25-OHD3

25-hydroxy vitamin D3

DN

diabetic nephropathy

ESRD

end stage renal disease

NL

nephrolithiasis

VDR

vitamin D receptor

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Not applicable

Author’s contribution

TH conceived the study, participated in data analysis and manuscript writing, SMN participated in data analysis and manuscript writing, AA participated in data analysis, SA participated in data compilation and manuscript writing, AAM participated in data analysis and manuscript writing, MOA participated in data analysis. NANA participated in data compilation and manuscript writing. All authors have read and approved the manuscript.

Funding

The authors extend their appreciation to the Deanship of Scientific Research at King Saud University for funding the work through the research group project No. RG-1439-74.

Funding Role: The funding body has provided the funds for data collection and analysis and has no role in design of the study, data interpretation and manuscript writing.

Availability of data and materials

All data generated or analyzed during this study are included in this manuscript.

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

References

1. Bikle DD Vitamin D metabolism, mechanism of action, and clinical applications Chem Biol 2014 21 3 319 329 10.1016/j.chembiol.2013.12.016 24529992 PMC3968073
2. Ogunkolade BW Boucher BJ Prahl JM Bustin SA Burrin JM Noonan K North BV Mannan N McDermott MF DeLuca HF Vitamin D receptor (VDR) mRNA and VDR protein levels in relation to vitamin D status, insulin secretory capacity, and VDR genotype in Bangladeshi Asians Diabetes 2002 51 7 2294 2300 10.2337/diabetes.51.7.2294 12086963
3. Chandel N Ayasolla K Wen H Lan X Haque S Saleem MA Malhotra A Singhal PC Vitamin D receptor deficit induces activation of renin angiotensin system via SIRT1 modulation in podocytes Exp Mol Pathol 2017 102 1 97 105 10.1016/j.yexmp.2017.01.001 28069388 PMC5331620
4. Yang L Wu L Fan Y Ma J Associations among four polymorphisms (BsmI, FokI, TaqI and ApaI) of vitamin D receptor gene and end-stage renal disease: a meta-analysis Arch Med Res 2015 46 1 1 7 10.1016/j.arcmed.2014.11.017 25434518
5. Yang L Wu L Fan Y Ma J Vitamin D receptor gene polymorphisms in association with diabetic nephropathy: a systematic review and meta-analysis BMC Med Genet 2017 18 1 95 10.1186/s12881-017-0458-8 28851298 PMC5575903
6. Zhou TB Jiang ZP Huang MF Association of vitamin D receptor BsmI (rs1544410) gene polymorphism with the chronic kidney disease susceptibility J Recept Signal Transduct Res 2015 35 1 54 57 10.3109/10799893.2014.926927 24918970
7. Nosratabadi R Arababadi MK Salehabad VA Shamsizadeh A Mahmoodi M Sayadi AR Kennedy D Polymorphisms within exon 9 but not intron 8 of the vitamin D receptor are associated with the nephropathic complication of type-2 diabetes Int J Immunogenet 2010 37 6 493 497 10.1111/j.1744-313X.2010.00953.x 20727043
8. Liu W Chen M Li M Ma H Tong S Lei Y Qi L Vitamin D receptor gene (VDR) polymorphisms and the urolithiasis risk: an updated meta-analysis based on 20 case-control studies Urolithiasis 2014 42 1 45 52 10.1007/s00240-013-0619-y 24190699
9. Zhang P Nie W Jiang H Effects of vitamin D receptor polymorphisms on urolithiasis risk: a meta-analysis BMC Med Genet 2013 14 104 10.1186/1471-2350-14-104 24093218 PMC3850980
10. Yin F Liu J Fan MX Zhou XL Zhang XL Association between the vitamin D receptor gene polymorphisms and diabetic nephropathy risk: a meta-analysis Nephrology (Carlton) 2018 23 2 107 116 10.1111/nep.13111 28703918
11. Liu Z Liu L Chen X He W Yu X Associations study of vitamin D receptor gene polymorphisms with diabetic microvascular complications: a meta-analysis Gene 2014 546 1 6 10 10.1016/j.gene.2014.05.052 24862218
12. Matana A Popovic M Torlak V Punda A Barbalic M Zemunik T Effects of genetic variants on serum parathyroid hormone in hyperparathyroidism and end-stage renal disease patients: a systematic review and meta-analysis Medicine (Baltimore) 2018 97 21 e10834 10.1097/MD.0000000000010834 29794776 PMC6392899
13. Guha M Bankura B Ghosh S Pattanayak AK Ghosh S Pal DK Puri A Kundu AK Das M Polymorphisms in CaSR and CLDN14 genes associated with increased risk of kidney stone disease in patients from the eastern part of India PLoS One 2015 10 6 e0130790 10.1371/journal.pone.0130790 26107257 PMC4480968
14. Han RDX Su B Yang W Liu H Song D Association between TaqI, ApaI of vitamin D receptor gene polymorphism and type 2 diabetic nephropathy of the Han nationality in Kunming Chin Med Herald 2015 12 9 69 72
15. Goknar N Oktem F Torun E Gok O Demir AD Kucukkoc M Kilic U The role of vitamin D receptor gene polymorphisms in Turkish infants with urolithiasis Ren Fail 2016 38 4 545 551 10.3109/0886022X.2016.1148557 26908058
16. Ozkaya O Soylemezoglu O Misirlioglu M Gonen S Buyan N Hasanoglu E Polymorphisms in the vitamin D receptor gene and the risk of calcium nephrolithiasis in children Eur Urol 2003 44 1 150 154 10.1016/S0302-2838(03)00206-9 12814692
17. Gunes S Bilen CY Kara N Asci R Bagci H Yilmaz AF Vitamin D receptor gene polymorphisms in patients with urolithiasis Urol Res 2006 34 1 47 52 10.1007/s00240-005-0033-1 16397775
18. Seyhan S Yavascaoglu I Kilicarslan H Dogan HS Kordan Y Association of vitamin D receptor gene Taq I polymorphism with recurrent urolithiasis in children Int J Urol 2007 14 12 1060 1062 10.1111/j.1442-2042.2007.01899.x 18036039
19. Aykan S Tuken M Gunes S Akin Y Ozturk M Seyhan S Yuruk E Temiz MZ Yilmaz AF Nguyen DP ApaL1 urokinase and Taq1 vitamin D receptor gene polymorphisms in first-stone formers, recurrent stone formers, and controls in a Caucasian population Urolithiasis 2016 44 2 109 115 10.1007/s00240-015-0813-1 26275878
20. Cakir OO Yilmaz A Demir E Incekara K Kose MO Ersoy N Association of the BsmI, ApaI, TaqI, Tru9I and FokI polymorphisms of the vitamin D receptor gene with nephrolithiasis in the Turkish population Urol J 2016 13 1 2509 2518 26945655
21. Tripathi G Sharma R Sharma RK Gupta SK Sankhwar SN Agrawal S Vitamin D receptor genetic variants among patients with end-stage renal disease Ren Fail 2010 32 8 969 977 10.3109/0886022X.2010.501934 20722565
22. Mittal RD Mishra DK Srivastava P Manchanda P Bid HK Kapoor R Polymorphisms in the vitamin D receptor and the androgen receptor gene associated with the risk of urolithiasis Indian J Clin Biochem 2010 25 2 119 126 10.1007/s12291-010-0023-0 23105897 PMC3453098
23. Wang LY, Zhang P, Wang HF, Qin ZW, Wei KB, Lv XA. Association of vitamin D receptor gene polymorphisms with end-stage renal disease and the development of high-turnover renal osteodystrophy in a Chinese population. Genet Mol Res. 2016;15(2) 10.4238/gmr.15026825 27323177
24. Martin RJ McKnight AJ Patterson CC Sadlier DM Maxwell AP Warren UKGSG A rare haplotype of the vitamin D receptor gene is protective against diabetic nephropathy Nephrol Dial Transplant 2010 25 2 497 503 10.1093/ndt/gfp515 19783860
25. Mossetti G Vuotto P Rendina D Numis FG Viceconti R Giordano F Cioffi M Scopacasa F Nunziata V Association between vitamin D receptor gene polymorphisms and tubular citrate handling in calcium nephrolithiasis J Intern Med 2003 253 2 194 200 10.1046/j.1365-2796.2003.01086.x 12542560
26. Moyano MJ Gomez de Tejada MJ Garcia Lozano R Moruno R Ortega R Marti V Sanchez Palencia R Miranda MJ Palma A Perez Cano R Alterations in bone mineral metabolism in patients with calcium kidney stone disease and polymorphism of vitamin D receptor. Preliminary results Nefrologia 2007 27 6 694 703 18336098
27. Bucan K Ivanisevic M Zemunik T Boraska V Skrabic V Vatavuk Z Galetovic D Znaor L Retinopathy and nephropathy in type 1 diabetic patients--association with polymorphysms of vitamin D-receptor, TNF, Neuro-D and IL-1 receptor 1 genes Coll Antropol 2009 33 Suppl 2 99 105 20120526
28. Zhang H Wang J Yi B Zhao Y Liu Y Zhang K Cai X Sun J Huang L Liao Q BsmI polymorphisms in vitamin D receptor gene are associated with diabetic nephropathy in type 2 diabetes in the Han Chinese population Gene 2012 495 2 183 188 10.1016/j.gene.2011.12.049 22245613
29. Ghorbanihaghjo A Argani H Samadi N Valizadeh S Halajzadeh J Yousefi B Rashtchizadeh N Relationship between vitamin D receptor gene FokI and ApaI polymorphisms and serum levels of fetuin-A, vitamin D, and parathyroid hormone in patients on hemodialysis Iran J Kidney Dis 2014 8 5 394 400 25194407
30. Singh PK van den Berg PR Long MD Vreugdenhil A Grieshober L Ochs-Balcom HM Wang J Delcambre S Heikkinen S Carlberg C Integration of VDR genome wide binding and GWAS genetic variation data reveals co-occurrence of VDR and NF-kappaB binding that is linked to immune phenotypes BMC Genomics 2017 18 1 132 10.1186/s12864-017-3481-4 28166722 PMC5294817
31. Tian Y Lv G Yang Y Zhang Y Yu R Zhu J Xiao L Zhu J Effects of vitamin D on renal fibrosis in diabetic nephropathy model rats Int J Clin Exp Pathol 2014 7 6 3028 3037 25031721 PMC4097221
32. Cinar N Harmanci A Yildiz BO Bayraktar M Vitamin D status and seasonal changes in plasma concentrations of 25-hydroxyvitamin D in office workers in Ankara, Turkey Eur J Intern Med 2014 25 2 197 201 10.1016/j.ejim.2013.11.004 24268953
33. Leary PF Zamfirova I Au J McCracken WH Effect of latitude on vitamin D levels J Am Osteopath Assoc 2017 117 7 433 439 10.7556/jaoa.2017.089 28662556
Publication and source details

Original title: Association of vitamin D receptor TaqI and ApaI genetic polymorphisms with nephrolithiasis and end stage renal disease: a meta-analysis

Tajamul Hussain; Shaik M. Naushad; Anwar Ahmed; Salman Alamery; Arif A. Mohammed; Mohamed O. Abdelkader; Nasser Abobakr Nasser Alkhrm

BMC Medical Genetics · 2019

© The Author(s). 2019https://creativecommons.org/licenses/by/4.0/Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.http://dx.doi.org/10.13039/501100011665Deanship of Scientific Research, King Saud UniversityRG-1439-74.Hussain Tajamul

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T18:34:30.058880+00:00

DOI: 10.1186/s12881-019-0932-6 · PMC6902508